LEVO Health

APRIL 18, 2024

This year, we’re thrilled to take our commitment a step further by sponsoring the 2024 HealthTech|X Accelerator program hosted by Tampa Bay Wave. By doing so, we aim to significantly enhance healthcare delivery and outcomes for clinicians and the patients they serve,” says David. Backed by the U.S.

Healthcare 98

Healthcare Healthcare Competition Training 98

PM360

SEPTEMBER 21, 2023

This article covers some of the reasons these drugs were chosen, how the process for price negotiation will occur, and the impact for the industry and for patients. They do not have biosimilar or generic competition available in the market. CMS will present an initial offer for each drug’s maximum fair price (MFP) by February 1, 2024.

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

Clarify Health

APRIL 18, 2024

As both government and commercial payers direct a greater share of volume to out-patient facilities and patient demand for same-day service increases, opportunity and competition in the ambulatory surgical center (ASC) space are increasing. Is there an ASC in your market you should merge with or acquire?

Marketing 52

Marketing Competition Physicians Management 52

PM360

MAY 10, 2024

May 9, 2024 /PRNewswire/ — VUE Health, a Boston-based healthcare advertising agency, has hired Zara Baker as Chief Digital Innovation Officer. Throughout her career, Zara has leveraged human-centered innovation to empower people and to realize her commitment to improve healthcare access for patients with unmet needs.

Healthcare 52

Healthcare Healthcare Biopharma Engineering 52

Healthcare Success

APRIL 8, 2024

As an engineering undergrad, I took a Marketing 101 class on a lark, seeking to better understand the psychology behind consumer behavior and developing products with a competitive edge. The 7 tactics of marketing can help you: Develop a competitive advantage. Promote that competitive edge with vigor. Reach a broader audience.

Marketing 112

Marketing Competition Patients Healthcare 112

European Pharmaceutical Review

JULY 18, 2022

Nebido is also patented until March 2024 in the European Union and until May 2027 in the United States. Too few of these patients receive appropriate treatment. We are committed to facilitating access to treatment for even more patients in need,” commented Gabriel Baertschi, CEO of Grünenthal.

Medicine 84

Medicine Physicians Competition Patients 84

PM360

DECEMBER 20, 2023

Learn more about why each company went with its respective strategy and the current outlook for each company in 2024 and beyond. The deal is expected to close in 2024. per patient on life-long standard of care. What is your outlook for 2024 and how do you believe companies can effectively differentiate themselves?

Management 109

Management Marketing Healthcare Healthcare 109

Clarify Health

JANUARY 16, 2024

in 2024, according to a report from Mercer — and that projection includes changes employers plan to make to hold down costs. The definition needs to include quality, patient outcomes and patient satisfaction, too. employers expect their health benefit cost per employee will jump an average of 5.4%

Networking 52

Networking Healthcare Healthcare Insurance 52

pharmaphorum

JANUARY 13, 2023

California Attorney General Rob Bonta (pictured above) said the conduct of the companies amounts to unlawful and deceptive business practices that violate the state’s unfair competition laws. The suit follows legal action over insulin pricing taken by other states, including Arkansas , Kansas, Mississippi, and Minnesota.

Manufacturing 105

Manufacturing Patients Medical Competition 105

pharmaphorum

JULY 11, 2022

NICE has updated its recommendations for NHS use of Johnson & Johnson’s IL-23 inhibitor Tremfya in the treatment of psoriatic arthritis (PsA), expanding the pool of patients eligible for treatment with the drug. J&J recorded worldwide Tremfya sales of $590 million in the first three months of 2022.

Patients 52

Patients Competition Marketing Sales 52

PM360

DECEMBER 20, 2023

With 2024 on the horizon, many in the biopharma space are taking stock of 2023 and what the current environment means for their potential success next year. This allows for a complementary portfolio fit without the kind of competitive overlap that comes under regulatory scrutiny from the FTC.

Biopharma 111

Biopharma Pharma Marketing Management 111

PM360

APRIL 7, 2023

However, we expect drugs without strong therapeutic alternatives to have an advantage in negotiations, while drugs in highly competitive classes will be negotiating from a weaker position. The business-to-business market leaders must find new and creative ways to help patients receive their treatments.

Manufacturing 97

Manufacturing Insurance Government Marketing 97

pharmaphorum

JULY 11, 2022

The company had been eyeing a possible regulatory filing for fitusiran this year, but has now set back the timeline – possibly until 2024 – while it gathers data on the revised dosing schedule, in the hope of maintaining efficacy with fewer clotting side effects. Sanofi acquired the drug when it bought Bioverativ in 2018 for $11.6

Engineering 52

Engineering Side effects Competition Sales 52

pharmaphorum

JANUARY 24, 2023

In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year, three key competitive issues for pharmaceutical companies in 2023 are assessed.

Medicine 97

Medicine Healthcare Healthcare Pharma 97

PM360

MARCH 22, 2024

MSL insights have the potential to deepen relationships with HCPs, ultimately enhancing patient health outcomes. The benefits of leveraging Medical Affairs data are multifaceted, transcending organizational and industry boundaries.

Medical 52

Medical Education Medical science Sales 52

pharmaphorum

NOVEMBER 17, 2022

Leela Barham argues that more transparency at a minimum is required next time around, should a VPAS style of agreement be agreed upon for 2024 onwards, and perhaps even a more radical re-think about how a deal is struck in the future. Patients, too, are calling for a role this time around. Predictable for government.

Government 98

Government Sales Medicine Consulting 98

pharmaphorum

JANUARY 16, 2023

The bi-weekly intramuscular shot – which was also approved in China in 2021 – will enter a crowded market for long-acing injectable (LAI) schizophrenia therapies in the US and have to take on heavyweight competition, including drugs that require less frequent dosing.

FDA 52

FDA Pharma Marketing Competition 52

Clarivate

DECEMBER 6, 2022

In a fiercely competitive U.S. These health systems combine multiple sites and services, and sometimes a health maintenance organization, to provide end-to-end care to patients locally or regionally. states and the United Kingdom and sees more than 35 million patient encounters per year. ChristianaCare, Wilmington, Delaware.

Networking 52

Networking Healthcare Healthcare Competition 52

PM360

APRIL 22, 2024

With a focus on patient-centricity, data-driven insights, and collaborative partnerships across the healthcare ecosystem, it’s redefining the playbook for market shaping and building advocacy for a product pre- and post-launch. Medical Affairs is at the forefront of this paradigm shift.

Medical 52

Medical Healthcare Healthcare Education 52

PM360

APRIL 22, 2024

In this issue, we take a closer look on the importance of patient education to Healthcare Professionals and navigating the challenges that arise. ABIGAIL MALLON Chief Patient Experience Officer, VMS BioMarketing Physician burnout is on the rise. The second to increase in patient-oriented communication and support for physicians.

Education 59

Education Physicians Healthcare Healthcare 59

Pharmaceutical Technology

JANUARY 10, 2023

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

Marketing 52

Marketing Physicians Leads Sales 52

pharmaphorum

NOVEMBER 1, 2022

“We believe that the top-line results as reported in and of themselves do not appear to appreciably differentiate NCX-470’s IOP-lowering competitive profile as a monotherapy” from current therapies like latanoprost and bimatoprost, he said in a research note.

Competition 52

Competition Safety FDA Leads 52

Pharmaceutical Technology

OCTOBER 28, 2022

The company expects to hold regulatory talks to shape its incoming Phase III program in adult patients in the second half of 2023. There, the business plans to submit an IND application for a Phase I/II in the second half of 2023, with a readout in 2024. Competition in an increasingly heated market.

Training 64

Training Marketing Competition FDA 64

Zymewire

FEBRUARY 8, 2024

My burning d esire was to test whether the exciting preclinical breakthrough discover ies we made at Boston Children’s Hospital and Harvard Medical School could truly help patients. What unmet needs are you hoping to address for patients? What were some of the obstacles faced early on?

Competition 52

Competition Leads Patients Marketing 52

Nixon Gwilt Law

JANUARY 16, 2024

What can digital health innovators and investors anticipate for the industry in 2024? What can digital health innovators and investors anticipate for the industry in 2024? Read on to find out what else is on our Legal Vision Board for 2024! The field is already saturated, so we will see companies exit as leaders emerge.

Healthcare 52

Healthcare Healthcare Management Insurance 52

pharmaphorum

NOVEMBER 25, 2022

The Parma site, as yet only nine months into construction, is due to become operational from 2024, with FDA, IFA, and EMA approvals due to be sought for 2025. In brief, the European plan for Chiesi is in-house drug development of biologicals and rare disease targeting. The situation was reversed only 25 years ago.

Pharmaceutical 98

Pharmaceutical Manufacturing Medicine Competition 98

PM360

NOVEMBER 13, 2023

Improving healthcare and patient outcomes requires that stakeholders communicate and collaborate, and GoodRx is one of the few places where providers, patients, and pharma can connect every single day. In addition, millions of their patients use GoodRx.

Media 52

Media Prescription Healthcare Provider Patients 52

Medico Reach

APRIL 21, 2022

And in this competitive digital era, email marketing is still one of the best strategies to boost your sales. However, handling competition is challenging whether you’re a marketer or a medical facility owner. You will be surprised to know that by 2024, the number of email users will grow up to 4.5 Boosts ROI.

Marketing 52

Marketing Healthcare Healthcare Sales 52

Infuse Medical

FEBRUARY 23, 2021

The Grand View Forecast states that the global market for medical animation is worth $514 million by 2024. Use 3D Animation to Educate Professionals and Patients. This allows you to not just tell medical professionals how your device is used, but actually show them in detail how the device can help them and their patients.

Medical 52

Medical Education Sales Marketing 52

Clarify Health

FEBRUARY 6, 2024

That way, they can continue to grow membership and thrive against the competition. Prior Authorization While an important tool for health plans to control costs and prevent fraud, waste, and abuse, the prior authorization process is burdensome for providers, health plans, and patients. And now, as of Jan.

Networking 52

Networking Insurance Government Management 52

Medico Reach

FEBRUARY 8, 2023

billion during 2020-2024. Big data can help clinical trial design, allowing researchers to leverage genetic makeup, historical patient data, past trial results, demographics, and more to find the right participants. The Grand View Research published a report highlighting the stark growth prospects of the pharma industry.

Pharma 52

Pharma Medicine Marketing Prospecting 52

PM360

SEPTEMBER 28, 2022

Patient behavior on insulin: Part D plans will have limited opportunity to adjust strategy for 2023, given bids are locked in. Behavioral response (patient adherence/persistence) to a lower out-of-pocket cost for insulin is unknown. Maximum patient Part D out-of-pocket set at $2,000.

Government 97

Government Manufacturing Prescription Competition 97

PM360

FEBRUARY 1, 2024

As we step into 2024, these insights pave the way for understanding the industry’s trajectory in the near future. Innovative trial methodologies, such as decentralised trials, have emerged as potential solutions to enhance patient recruitment and retention. Addressing these challenges necessitates a multifaceted approach.

Recruitment 52

Recruitment Healthcare Healthcare Management 52

pharmaphorum

JULY 19, 2022

Some big biosimilar launches – including versions of AbbVie’s immunology blockbuster Humira (adalimumab), Bayer’s ophthalmology drug Eylea (aflibercept) and Biogen’s multiple sclerosis therapy Tysabri (natalizumab) aren’t due to take place until 2023 or 2024. billion despite a more competitive marketplace.

Sales 98

Sales Competition Medicine Pharma 98

European Pharmaceutical Review

FEBRUARY 7, 2023

Some of the current and anticipated proposals will not be adopted in 2023, or even before the end of tenure of the current European Commission in late 2024. In addition, the devices must not present an unacceptable risk to patient and user health and safety as established in Articles 94 and 95 of the MDR. of the MDR and Article 110.4

Government 97

Government Medical Medicine Marketing 97

Clarivate

MAY 8, 2024

A glance at the 2023 and early 2024 life science dealmaking environment shows fewer, but higher-value, transactions. A prime example of strategic spending is Merck & Co./MSD, MSD, which continued its spending spree to strengthen its oncology portfolio.

Pharma 59

Pharma Biopharma Prospecting Competition 59

Clarify Health

DECEMBER 5, 2023

They will help strengthen efforts to access and analyze this valuable healthcare price data for patients and other stakeholders. Updated hospital price transparency regulations One of the most significant developments starts on July 1, 2024, when hospitals must use standardized access and data schemas.

Healthcare 52

Healthcare Healthcare Competition Insurance 52